A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
PHASE3CompletedINTERVENTIONAL
Enrollment
141
Participants
Timeline
Start Date
August 31, 2001
Study Completion Date
October 31, 2002
Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG
risperidone
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00034775 - A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. | Biotech Hunter | Biotech Hunter